Clinical trial NCT00136591: A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Official title: A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Follicular Lymphoma
Keywords: follicular lymphoma
bortezomib
relapse
Lead sponsor: Lymphoma Study Association
Sponsor class: OTHER
Collaborators: name: Janssen-Cilag International NV
First posted: 2005-08-29
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, randomized, sequential, international, multicentric, 2-arm, non-comparative, open-label, 2-stage clinical study to determine disease response rates to Velcade™ therapy in subjects who have relapsed or refractory follicular B-cell lymphoma.

Qualitative comparisons of the 2 treatment arms based on safety, efficacy and dosing convenience will be made in order to recommend a dose schedule for further clinical study.

Detailed description: This is a prospective, randomized, sequential, international, multicentric, 2-arm, non-comparative, open-label, 2-stage clinical study to determine disease response rates therapy of Velcade™ in subjects who have relapsed or refractory follicular B-cell lymphoma (FLL).

Qualitative comparisons of the 2 treatment arms based on safety, efficacy and dosing convenience will be made in order to recommend a dose schedule for further clinical study.

It is anticipated that approximatively 120 subjects will be enrolled to achieve the required 110 evaluable subjects, 55 in each treatment arm. Patients who receive any amount of Velcade™ are evaluable. Subjects not evaluable for response will be replaced.

A central randomization will be used in this study. Subjects will be randomized and stratified with factors for prior therapies (1 or 2 versus \> 2) and time to progression (TPP) for the last given anti-neoplastic therapy (≤ 12 months versus \> 12 months).

The eligible subjects will be randomized to either Treatment Arm A or Treatment Arm B in a 1:1 ratio:

* Subjects randomized to Treatment Arm A will receive 1.5 mg/m² Velcade™ administered biweekly on Days 1, 4, 8, and 11 of a 21-day cycle. Patients will receive 8 cycles. The dose of Velcade™ received in schedule A will be 48 mg/m² over 24 weeks.
* Subjects randomized to Treatment Arm B will receive 1.6 mg/m² Velcade™ administered weekly on Days 1, 8, 15, and 22 of a 35-day cycle. Patients will receive 6 cycles. The dose of Velcade™ received in schedule B will be 38.4 mg/m² over 30 weeks.

Two additional cycles may be administered if the patient shows improvement to PR after 8 or 6 cycles for arm A or B, respectively.

Study drug dose and schedule reduction for toxicity will be allowed during the study.

A two stage interim analysis will be conducted in each treatment arm to determine whether either of the 2 treatments lacks sufficient efficacy.

The final analysis will be conducted when all subjects have had the opportunity to complete the 30 day post-treatment evaluation visit. All data from all visits up until this point will be used in the final analysis, including data from any follow-up visits that have occurred.

Patients will be recruited approximately over 2 years and followed until all data are available for final analysis.

The total duration of the study is expected to be 5 years.

Eligibility criteria: Inclusion Criteria:

* Male or female subject 18 years or older.
* Initial diagnosis of follicular B-cell lymphoma (CD20+) (grades 1, 2, and 3 based on the World Health Organization 1997 classification), in first or subsequent relapse or progression after prior anti-neoplastic treatment including previous rituximab treatment. Relapse or progression since previous anti-neoplastic therapy must be documented by new lesions or objective evidence of progression of existing lesions.
* At least 1 measurable lymph node mass that is \>1.5 cm in 2 perpendicular dimensions, and has not been previously irradiated or has grown since previous irradiation.
* No active central nervous system (CNS) lymphoma
* Karnofsky Performance Status (KPS) \>50% (Eastern Cooperative Oncology Group \[ECOG\] 0-2)
* The following laboratory values at screening, unless abnormalities are related to the lymphoma:

  * Absolute neutrophil count (ANC) \>1000 cells/dL;
  * Platelets \>50,000 cells/dL;
  * Aspartate transaminase (AST) \<3 x upper limit of normal (ULN);
  * Alanine transaminase (ALT) \<3 x ULN;
  * Total bilirubin \<2 x ULN;
  * Creatinine level \<150 µmol/L
* Toxic effects of previous therapy or surgery resolved to Grade 2 or better.
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Women are neither breast feeding nor pregnant for the duration of the study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Male subject agrees to use an acceptable method of contraception for the duration of the study.
* Voluntary signed informed consent before performance of any study-related procedure not part of normal medical care.
* Patient with minimum life expectancy of 3 months.

Exclusion Criteria:

* Any other type of lymphoma.
* Previous treatment with Velcade™.
* Anti-neoplastic or experimental or radiation therapy within 3 weeks before Day 1 of Cycle 1.
* Major surgery within 2 weeks before Day 1 of Cycle 1.
* Rituximab, alemtuzumab (Mabcampath®), or other unconjugated therapeutic antibody within 10 weeks before Day 1 of Cycle 1.
* Nitrosoureas within 6 weeks before Day 1 of Cycle 1.
* Radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin™), or tositumomab (Bexxar®) within 10 weeks before Day 1 of Cycle 1.
* Peripheral neuropathy or neuropathic pain of Grade 3 or worse.
* History of allergic reaction attributable to compounds containing boron or mannitol.
* Diagnosed or treated for a malignancy other than non-Hodgkin's lymphoma (NHL) within 5 years before Day 1 of Cycle 1, with the exception of complete resection of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy.
* Active systemic infection requiring treatment.
* Previously known HIV positive serology.
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
* Concurrent treatment with another investigational agent.
* Adult patient under guardian.

Primary outcomes:
measure: To determine the response rate to Velcade™ as a single agent
timeFrame: End of treatment
Secondary outcomes:
measure: To determine the overall complete response (CR) rate (CR + complete response unconfirmed [CRu])
timeFrame: End of treatment
measure: To determine time to progression (TTP)
timeFrame: End of study
measure: To determine overall survival
timeFrame: End of study
measure: To determine duration of response
timeFrame: End of study
measure: To determine the time to best response
timeFrame: End of study
measure: To evaluate the safety and tolerability of Velcade™
timeFrame: End of study
measure: To evaluate the effects of Velcade™ given biweekly at 1.5 mg/m2 versus 1.6 mg/m2 weekly
timeFrame: End of study
Other outcomes:
Locations:
city: Mont-Godinne
country: Belgium
facility: Groupe d'Etude des Lymphomes de l'adulte
city: Pierre-Bénite cedex
country: France
facility: Service d'Hématologie - Centre Hospitalier Lyon-Sud
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Hospices Civils de Lyon, Lyon, France
name: Bertrand Coiffier, MD
role: STUDY_CHAIR
affiliation: Institut Gustave Roussy, Villejuif, France
name: Vincent Ribrag, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005 Feb 1;23(4):676-84. doi: 10.1200/JCO.2005.02.050. Epub 2004 Dec 21.
citation: Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21.